China Chemical Synthesis Biotechnology Co., Ltd. Q4 2025 EPS -NT$4.39
China Chemical Synthesis Biotechnology Co., Ltd. (1762) reported its Q4 2025 financial results, with basic earnings per share (EPS) at -NT$4.39. The company's revenue was NT$805 million, and net loss after tax was NT$244 million.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:20 (16h 20m after Collected)
China Chemical Synthesis Biotechnology Co., Ltd. (Stock Code: 1762), a company in the biotechnology and healthcare industry, announced its financial results for the fourth quarter of 2025. The basic earnings per share (EPS) for the quarter were -NT$4.39. Revenue was NT$805 million, and the company reported a net loss after tax of NT$244 million.
FAQ
What is China Chemical Synthesis Biotechnology's stock code?
China Chemical Synthesis Biotechnology's stock code is 1762.
What industry does China Chemical Synthesis Biotechnology belong to?
China Chemical Synthesis Biotechnology belongs to the biotechnology and healthcare industry.
What were China Chemical Synthesis Biotechnology's Q4 2025 earnings per share?
China Chemical Synthesis Biotechnology's Q4 2025 basic earnings per share (EPS) were -NT$4.39.
What was China Chemical Synthesis Biotechnology's revenue in Q4 2025?
China Chemical Synthesis Biotechnology's revenue in Q4 2025 was NT$805 million.
What was China Chemical Synthesis Biotechnology's net loss after tax in Q4 2025?
China Chemical Synthesis Biotechnology's net loss after tax in Q4 2025 was NT$244 million.